STATEMENT OF NEED
An estimated 77,240 new cases of non-Hodgkin lymphoma (NHL) are diagnosed each year in the United States. A number of disease subtypes exist, including follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). An indolent, difficult-to-treat B-cell malignancy, FL comprises approximately 22% of all cases of NHL. Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory FL. However, the risk for comorbidities and secondary cancers limits the use of this treatment upfront, and further research is required to keep the remission rate among FL patients high and durable. CLL, which represents approximately 37% of all adult leukemias in the United States, is considered primarily a disease of older patients, with a median age at diagnosis of 70 years. With the treatment of older patients complicated by comorbidities such as diabetes and heart disease, the prevalence and mortality of CLL are expected to increase in the coming decade in conjunction with the aging population.
Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Upon completion of this activity, participants should be able to:
Amy L. Goodrich, RN, MSN, CRNP-AC (Chairperson)
Johns Hopkins Kimmel Cancer Center
There is no fee to participate in or claim NCPD credit for this activity.
Nursing Continuing Professional Development
i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this NCPD activity. This activity has been designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of a NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
Amy L. Goodrich, RN, MSN, CRNP-AC, discloses that she has served on the advisory board for AstraZeneca and Janssen. She has also served as a consultant for AbbVie and Janssen.
The i3 Health planners and managers have nothing to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
UNAPPROVED USE DISCLOSURE
i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Verastem.
Aggregate participant data will be shared with commercial supporters of this activity.